See today's BioWorld
To read the full story, subscribe or sign in.

Astellas, Frequency in worldwide agreement targeting hearing loss

July 18, 2019
By Lee Landenberger
Astellas Pharma Inc. and Frequency Therapeutics Inc. have agreed to develop and commercialize Frequency's regenerative therapeutic candidate, FX-322, to treat sensorineural hearing loss (SNHL).
BioWorld Deals and M&A Collaboration